Skip to main content
Erschienen in: Reactions Weekly 1/2011

01.09.2011 | Case report

Bevacizumab/irinotecan

Interstitial pneumonitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literatur
1.
Zurück zum Zitat Tamura J, Nakauchi M, Nakayama Y, Kitaguchi K, Sakikubo M, Ura K, Taira K, Ohe H, Yoshikawa A, Ishigami S-I, Baba N.A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer. Gan to Kagaku Ryoho 36: 2665-2668, No. 13, Dec 2009 - Japan Tamura J, Nakauchi M, Nakayama Y, Kitaguchi K, Sakikubo M, Ura K, Taira K, Ohe H, Yoshikawa A, Ishigami S-I, Baba N.A case of interstitial pneumonitis induced by FOLFIRI+bevacizumab combination therapy for liver and lung metastasis of colon cancer. Gan to Kagaku Ryoho 36: 2665-2668, No. 13, Dec 2009 - Japan
Metadaten
Titel
Bevacizumab/irinotecan
Interstitial pneumonitis: case report
Publikationsdatum
01.09.2011
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2011
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201113670-00029

Weitere Artikel der Ausgabe 1/2011

Reactions Weekly 1/2011 Zur Ausgabe

Case report

Ipilimumab

Case report

BCG vaccine

Case report

Antineoplastics

Case report

Sulprostone